June #135 : B Careful - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Jagged Little Pills

Happy Feet

Bunny Business

Playing the Percentages

Soul Survivors

B Careful

In the Running

Seeing Double

Write of Passage

Salad Daze

From Here to Paternity

Summer Share

Papa, Can You Hear Me?

Outside Chance

Send Us the Bill

Climb Every Mountain

Farewell Tour

Hot Dates-June 2007

Agent Provocateur

Mixed (Up) Media

Another AIDS Movie for Philadelphia

Say What?!-June 2007

Attention, K-Y Shoppers

The Next Best Thing to Being There

Getting Crafty

Baggage Claim

Editor's Letter-June 2007

Mailbox-June 2007

Catch of the Month—June 2007

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2007

B Careful

by Laura Whitehorn

A Hepatitis B med may breed HIV drug resistance

Do you fit this description: You have both HIV and hepatitis B (HBV), don’t need to take HIV meds but do need treatment for hep B? If so, avoid the new HBV med Baraclude (entecavir)—at least for now. A recent study by researchers at Johns Hopkins School of Medicine in Baltimore showed that Baraclude suppresses HIV along with HBV.

That may sound good, but it means that taking Baraclude solo—without additional HIV meds—could allow your HIV to become resistant to the drug and other nukes. (HIV monotherapy can lead to drug resistance.) That, in turn, could limit your choices when you do begin HIV meds. Scientists originally thought Baraclude suppressed HBV but not HIV, setting it apart from some other HBV drugs (Hepsera and Epivir-HBV), which attack both viruses.

The new data prompted Bristol-Myers Squibb, maker of Baraclude, to alert HIV docs to the problem in February. But BMS’s Richard Colonno, PhD, says that more investigation is needed. In ten years of testing Baraclude, Colonno says, BMS never found evidence that it suppresses HIV. BMS and Hopkins researchers will team up to resolve the conflict.  

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.